Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held by Aclaris Therapeutics, Inc. on June 2, 2022. The filing details the voting results for three proposals submitted to security holders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a corporate governance report regarding shareholder voting outcomes.
Material Changes and Voting Results
Of the 61,741,724 shares outstanding, 56,783,174 shares (91.96%) were present or represented by proxy. The results for the three proposals were as follows:
- Proposal 1 (Election of Directors): All three nominees (Neal Walker, William Humphries, and Andrew Schiff, M.D.) were elected to serve until the 2025 annual meeting.
- Proposal 2 (Executive Compensation): The advisory approval of named executive officer compensation was approved with 49,767,261 votes for, 1,004,918 votes against, and 14,013 abstentions.
- Proposal 3 (Auditor Ratification): The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified with 56,771,419 votes for, 2,484 votes against, and 9,271 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific terms of the executive compensation package approved in Proposal 2 by reviewing the definitive proxy statement filed on April 21, 2022.
- Confirm the tenure of the newly elected directors, which extends until the 2025 annual meeting.
- Note the high level of shareholder participation, with 91.96% of outstanding shares represented at the meeting.